Skip to main content
. 2017 Jan 2;8(7):11977–11989. doi: 10.18632/oncotarget.14450

Figure 6. Kaplan-Meier plots of breast cancer patient survival based on LOXL4, collagen I, and collagen IV expression in the BreastMark dataset.

Figure 6

A. Low LOXL4 expression was associated with poor overall survival (OS) in breast cancer. n = 584, number of events = 169, Hazard ratio (HR) = 0.6395 (0.4704-0.8694), score (log rank) test = 8.28, P = 0.004. B. The combination of low LOXL4 and high collagen I expression was associated with poor OS in breast cancer. n = 584, number of events = 169, HR = 0.6718 (0.4612-0.9787), score (log rank) test = 0.08, P = 0.037. C. The combination of low LOXL4 and high collagen IV expression was associated with poor OS in breast cancer. n = 584, number of events = 169, HR = 0.6619 (0.4483-0.9774), score (log rank) test = 15.36, P = 0.036. D. Low expression of LOXL4 was associated with a poor OS in triple negative breast cancer (TNBC). n = 101, number of events = 36, HR = 0.427 (0.2207-0.8259), score (log rank) test = 6.78, P = 0.009. E. The combination of low LOXL4 and high collagen I expression showed a trend towards association with poor OS in TNBC. n = 101, number of events = 36, HR=0.4621 (0.2018-1.058), score (log rank) test = 3.5, P = 0.061. F. The combination of low LOXL4 and high collagen IV expression was associated with a poor OS in TNBC. n = 101, number of events = 36, HR = 0.3006 (0.1166-0.7749), score (log rank) test = 6.96, P = 0.008.